Cointime

AlloVir

company

About

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.

  • 101 - 250

Highlights

Total Funding Amount
$126.60M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$126.60M
Industries
Biotechnology,Clinical Trials,Pharmaceutical
Founded date
Jan 1, 2013
Number Of Employee
101 - 250
Operating Status
Active

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.

The company was founded in 2013 and headquartered in Houston, Texas.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$126.60M
AlloVir has raised a total of $126.60M in funding over 2 rounds. Their latest funding was raised on Jul 27, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 27, 2022 Post-IPO Equity $126.60M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
AlloVir is funded by 1 investors. Kite Pharma are the most recent investors.
Investor Name Lead Investor Funding Round
Kite Pharma — Post-IPO Equity
Cointime
เนื้อหา
บริษัท